The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Abstract: Immune checkpoint molecules represent physiological brakes of the immune system that are essential for the maintenance of immune homeostasis and prevention of autoimmunity. By inhibiting these negative regulators of the immune response, immune checkpoint blockade can increase anti-tumor immunity, but has been primarily successful in solid cancer therapy and Hodgkin lymphoma so far. Allogeneic hematopoietic cell transplantation (allo-HCT) is a well-established cellular immunotherapy option with the potential to cure hematological cancers, but relapse remains a major obstacle. Relapse after allo-HCT is mainly thought to be attributable to loss of the graft-versus-leukemia (GVL) effect and hence escape of tumor cells from the allogeneic immune response. One potential mechanism of immune escape from the GVL effect is the inhibition of allogeneic T cells via engagement of inhibitory receptors on their surface including PD-1, CTLA-4, TIM3, and others. This review provides an overview of current evidence for a role of immune checkpoint molecules for relapse and its treatment after allo-HCT, as well as discussion of the immune mediated side effect graft-vs.-host disease. We discuss the expression of different immune checkpoint molecules on leukemia cells and T cells in patients undergoing allo-HCT. Furthermore, we review mechanistic insights gained from preclinical studies and summarize clinical trials assessing immune checkpoint blockade for relapse after allo-HCT
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Frontiers in immunology. - 12 (2021) , 634435, ISSN: 1664-3224
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- DOI
-
10.3389/fimmu.2021.634435
- URN
-
urn:nbn:de:bsz:25-freidok-1947017
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:54 PM CET
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
Time of origin
- 2021
Other Objects (12)
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Immune checkpoint inhibitor induced neurocognitive deficits in patients
Advances in understanding the pathogenesis of graft‐versus‐host disease
The Hematopoietic niche in myeloproliferative neoplasms
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
MiRNA-146a is a crucial regulator of immune-related adverse events caused by immune checkpoint inhibitor therapy
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Immune checkpoint inhibitor induced neurocognitive deficits in patients
Advances in understanding the pathogenesis of graft‐versus‐host disease
The Hematopoietic niche in myeloproliferative neoplasms
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
MiRNA-146a is a crucial regulator of immune-related adverse events caused by immune checkpoint inhibitor therapy
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Immune checkpoint inhibitor induced neurocognitive deficits in patients
Advances in understanding the pathogenesis of graft‐versus‐host disease
The Hematopoietic niche in myeloproliferative neoplasms
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
MiRNA-146a is a crucial regulator of immune-related adverse events caused by immune checkpoint inhibitor therapy
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study